Terlipressin vs. octreotide in bleeding esophageal varices as an adjuvant therapy with endoscopic band ligation: a randomized double-blind placebo-controlled trial.

Abid S, Jafri W, Hamid S, Salih M, Azam Z, Mumtaz K, Shah HA, Abbas Z

The American journal of gastroenterology17 Feb 2009Cited by 52 (Europe PMC)

PMID19223890DOI10.1038/ajg.2008.147PepBankPUB-19223890

Publisher page PubMedAsk about this study

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study5

5 results from studies that gave the peptide. 5 results from people.

01HumanRandomized controlled trialSafety outcome
In cirrhotic patients with variceal bleeding, deaths occurred in 7 octreotide patients (4.3%) versus 9 terlipressin patients (5.5%), without significance.
In plain wordsIn cirrhotic patients with variceal bleeding, deaths were numerically fewer with octreotide than terlipressin, without a significant difference.
Peptide
Octreotide
Outcome
DecreaseIn-hospital deaths
Study
n = 324
Comparator
terlipressin with band ligation
Outcome group
Mortality · Gastrointestinal
Studied dose
Dose not stated
Measurements
Deaths
7 patients
octreotide group (group B)
Deaths
4.3%
octreotide group (group B)
Deaths
9 patients
terlipressin group (group A)
Deaths
5.5%
terlipressin group (group A)
P value
0.626 P
octreotide versus terlipressin
Source sentences
Summary
Overall sixteen patients died (three failure to control bleed and thirteen from causes other than variceal bleed); nine in group A (5.5%) and seven (4.3%) in group B (P=0.626).
2 context sentences(design, population, supporting numbers)
Summary · context
Cirrhotic patients with esophageal variceal bleed were randomized on admission to receive terlipressin (group A) or octreotide (group B) along with the placebo in the other arm in a double-blind fashion.
Summary · context
A total of 324 patients were enrolled; 163 in the terlipressin group (group A) and 161 in the octreotide group (group B).
Report a problemFND-1922389001
02HumanRandomized controlled trialEfficacy outcome
In cirrhotic patients, octreotide controlled variceal bleeding in 154 patients (95.6%) versus 151 (92.63%) with terlipressin.
In plain wordsIn cirrhotic patients, bleeding control was numerically more frequent with octreotide than terlipressin.
Peptide
Octreotide
Outcome
IncreaseControl of variceal bleed
Study
n = 324
Comparator
terlipressin with band ligation
Outcome group
Gastrointestinal protection · Gastrointestinal
Studied dose
Dose not stated
Measurements
Control of variceal bleed
154 patients
octreotide group (group B)
Control of variceal bleed
95.6%
octreotide group (group B), intention to treat
Control of variceal bleed
151 patients
terlipressin group (group A)
Control of variceal bleed
92.63%
terlipressin group (group A), intention to treat
Confidence interval
0.219 to 1.492
octreotide versus terlipressin, as reported
Source sentences
Summary
In the intention to treat analysis, "control of variceal bleed" was noted in 305 patients (94.13%); 151 (92.63%) patients in group A and 154 (95.6%) patients in group B (confidence interval: 0.219-1.492).
2 context sentences(design, population, supporting numbers)
Summary · context
Cirrhotic patients with esophageal variceal bleed were randomized on admission to receive terlipressin (group A) or octreotide (group B) along with the placebo in the other arm in a double-blind fashion.
Summary · context
A total of 324 patients were enrolled; 163 in the terlipressin group (group A) and 161 in the octreotide group (group B).
Report a problemFND-1922389002
03HumanRandomized controlled trialEfficacy outcome
In cirrhotic patients with variceal bleeding, transfusions averaged 3.9±2.5 units with octreotide versus 3.7±2.3 with terlipressin, without significance.
In plain wordsIn cirrhotic patients with variceal bleeding, transfusions were numerically higher with octreotide than terlipressin, without a significant difference.
Peptide
Octreotide
Outcome
IncreasePacked cell transfusions
Study
n = 324
Comparator
terlipressin with band ligation
Outcome group
Gastrointestinal protection · Gastrointestinal
Studied dose
Dose not stated
Measurements
Packed cell transfusions
3.9 units
octreotide group (group B), SD 2.5
Packed cell transfusions
3.7 units
terlipressin group (group A), SD 2.3
P value
0.273 P
octreotide versus terlipressin
Source sentences
Summary
Packed cell transfusions in group A were 3.7+/-2.3 units, whereas in group B there were 3.9+/-2.5 units (P=0.273).
2 context sentences(design, population, supporting numbers)
Summary · context
Cirrhotic patients with esophageal variceal bleed were randomized on admission to receive terlipressin (group A) or octreotide (group B) along with the placebo in the other arm in a double-blind fashion.
Summary · context
A total of 324 patients were enrolled; 163 in the terlipressin group (group A) and 161 in the octreotide group (group B).
Report a problemFND-1922389003
04HumanRandomized controlled trialEfficacy outcome
In cirrhotic patients with variceal bleeding, hospital stay was significantly longer with octreotide (126.39±47.45 h) than terlipressin (108.40±34.81 h).
In plain wordsIn cirrhotic patients with variceal bleeding, hospital stays were longer with octreotide than terlipressin.
Peptide
Octreotide
Outcome
IncreaseHospital stay
Study
n = 324
Comparator
terlipressin with band ligation
Outcome group
Intensive care and hospital outcomes · Gastrointestinal
Studied dose
Dose not stated
Measurements
Length of hospital stay
126.39 h
octreotide group (group B), SD 47.45
Length of hospital stay
108.4 h
terlipressin group (group A), SD 34.81
P value
≤ 0.001 P
octreotide versus terlipressin
Source sentences
Summary
Length of hospital stay in groups A and B was 108.40+/-34.81 and 126.39+/-47.45 h, respectively (P< or =0.001).
2 context sentences(design, population, supporting numbers)
Summary · context
Cirrhotic patients with esophageal variceal bleed were randomized on admission to receive terlipressin (group A) or octreotide (group B) along with the placebo in the other arm in a double-blind fashion.
Summary · context
A total of 324 patients were enrolled; 163 in the terlipressin group (group A) and 161 in the octreotide group (group B).
Report a problemFND-1922389004
05HumanRandomized controlled trialSafety outcome
In cirrhotic patients with variceal bleeding, neither octreotide nor terlipressin produced observed cardiovascular side effects.
In plain wordsIn cirrhotic patients with variceal bleeding, no cardiovascular side effects were observed with either octreotide or terlipressin.
Peptide
Octreotide
Outcome
Not applicableCardiovascular side effects
Study
n = 324
Comparator
terlipressin with band ligation
Outcome group
Adverse events · Cardiovascular
Studied dose
Dose not stated
Source sentences
Summary
No cardiovascular side effects were observed in either group.
2 context sentences(design, population, supporting numbers)
Summary · context
Cirrhotic patients with esophageal variceal bleed were randomized on admission to receive terlipressin (group A) or octreotide (group B) along with the placebo in the other arm in a double-blind fashion.
Summary · context
A total of 324 patients were enrolled; 163 in the terlipressin group (group A) and 161 in the octreotide group (group B).
Report a problemFND-1922389005

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Registered trials2

Trials this study reports on, or that list this study as a reference. Registry data from ClinicalTrials.gov.

2 trials · source ClinicalTrials.gov (opens in a new tab)

Status unknownPhase 4NCT04028323

Functional MRI-based Assessment of Terlipressin vs. Octreotide on Renal Function in Cirrhotic Patients With Acute Variceal Bleeding (CHESS1903)

Nanfang Hospital, Southern Medical Universityn = 6016 Jul 2019 to est. 15 Oct 2022

Renal Function Disorder · Acute Variceal Bleeding

Trial page ClinicalTrials.govUpdated 17 Aug 2021

Status unknownPhase not statedNCT02311608

Effects of Terlipressin When Usual Somatostatin or Octreotide Dose Fails

Shanghai Zhongshan Hospitaln = 1,320Feb 2014 to est. Jun 2016

Liver Cirrhosis · Esophageal and Gastric Varices · Hemorrhage

Trial page ClinicalTrials.govUpdated 8 Dec 2014

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
28 Oct 2026, 02:03 UTC
Study results updated
Version 1
27 Oct 2026, 16:36 UTC
First added · source update from Europe PMC

PepBank is a research reference. Talk to a doctor before you use any peptide.